Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Abvc Biopharma Inc (ABVC)
Abvc Biopharma Inc (ABVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,835
  • Shares Outstanding, K 7,744
  • Annual Sales, $ 970 K
  • Annual Income, $ -16,420 K
  • 60-Month Beta 0.78
  • Price/Sales 5.95
  • Price/Cash Flow N/A
  • Price/Book 0.68
Trade ABVC with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1900 +0.84%
on 02/20/24
1.5400 -22.08%
on 01/31/24
-0.0500 (-4.00%)
since 01/19/24
3-Month
1.0000 +20.00%
on 12/12/23
2.4500 -51.02%
on 01/03/24
-0.4900 (-28.99%)
since 11/20/23
52-Week
0.6739 +78.07%
on 10/06/23
9.6000 -87.50%
on 05/09/23
-6.0500 (-83.45%)
since 02/17/23

Most Recent Stories

More News
ABVC Biopharma (NASDAQ: ABVC) Inks Major Licensing Agreement with Xinnovation Therapeutics for ABV-1504 and ABV-1505

Landmark Licensing Deal for ABVC in China's Growing Healthcare Market ABVC Biopharma, Inc. (NASDAQ: ABVC), a pioneer in the development

ABVC : 1.2000 (-5.51%)
ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

/PRNewswire/ -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS,...

ABVC : 1.2000 (-5.51%)
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

/PRNewswire/ -- ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...

ABVC : 1.2000 (-5.51%)
ABVC BioPharma Provides Vitargus® Update

Phase II Vitargus® Clinical Study Protocol Receives Local Ethics Committee Approval FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire...

ABVC : 1.2000 (-5.51%)
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028

-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc....

ABVC : 1.2000 (-5.51%)
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company...

ABVC : 1.2000 (-5.51%)
Zacks Places Share Value of ABVC BioPharma at $9.50

FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company...

ABVC : 1.2000 (-5.51%)
ABVC BioPharma Provides Vitargus® Update

Vitargus® Receives Phase II Thailand Central Research Ethics Committee Approval  FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...

ABVC : 1.2000 (-5.51%)
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation

FREMONT, CA, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company...

ABVC : 1.2000 (-5.51%)
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC

FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company...

ABVC : 1.2000 (-5.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

ABCV BIOPHARMA identifies & commercializes drugs & medical devices developed. ABCV BIOPHARMA, formerly known as AMER BRIVISION, is based in FREMONT, CA.

See More

Key Turning Points

3rd Resistance Point 1.3467
2nd Resistance Point 1.3133
1st Resistance Point 1.2567
Last Price 1.2000
1st Support Level 1.1667
2nd Support Level 1.1333
3rd Support Level 1.0767

See More

52-Week High 9.6000
Fibonacci 61.8% 6.1902
Fibonacci 50% 5.1369
Fibonacci 38.2% 4.0837
Last Price 1.2000
52-Week Low 0.6739

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar